Fulcrum Therapeutics Inc. (FULC)
3.06
0.02 (0.66%)
At close: Apr 16, 2025, 3:59 PM
3.01
-1.51%
After-hours: Apr 16, 2025, 04:08 PM EDT
0.66% (1D)
| Bid | 3 |
| Market Cap | 165.18M |
| Revenue (ttm) | 80M |
| Net Income (ttm) | -9.72M |
| EPS (ttm) | -0.16 |
| PE Ratio (ttm) | -19.12 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.07 |
| Volume | 165,000 |
| Avg. Volume (20D) | 408,354 |
| Open | 3.02 |
| Previous Close | 3.04 |
| Day's Range | 2.95 - 3.10 |
| 52-Week Range | 2.31 - 10.13 |
| Beta | 2.13 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell di...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2019
Employees 45
Stock Exchange NASDAQ
Ticker Symbol FULC
Website https://www.fulcrumtx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for FULC stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 30.72% from the latest price.
Stock Forecasts6 months ago
+15.27%
Fulcrum Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
7 months ago
-7.56%
Fulcrum Therapeutics shares are trading lower after HC Wainwright & Co and RBC Capital downgraded the company and lowered their respective price targets on the stock.
